Sentences with phrase «with leading cancer centers»

Not exact matches

She also plays an active part in the Trevor Project and has worked with the L.A Gay & Lesbian Center concerning homeless LGBT youth, has conducted fundraising for Susan G. Komen in honor of October being Breast Cancer Awareness month and recently led this year's 30th annual Aids Walk Los Angeles, cutting the starting ribbon for over 25,000 walkers.

That's how Charles Sawyers, a 2009 Lasker Award winner and chair of human oncology and pathogenesis at Memorial Sloan - Kettering Cancer Center in New York City, made the connection with Bristol Myers Squibb (BMS) that led to second - generation treatments for chronic myeloid leukemia (CML).

And a team led by Moss and U. of C. Medical Center assistant professor of medicine Patrick Singleton as well as other groups, have also given drugs that block opioid receptors to mice with cancer.

«These findings suggest that many men with intermediate risk prostate cancer can be well managed with seed implant alone and do not require the addition of external beam radiation,» said Bradley Prestidge, MD, lead author of the study and Medical Director of the Bon Secours Cancer Institute at DePaul Medical Center in Norfolk, Vircancer can be well managed with seed implant alone and do not require the addition of external beam radiation,» said Bradley Prestidge, MD, lead author of the study and Medical Director of the Bon Secours Cancer Institute at DePaul Medical Center in Norfolk, VirCancer Institute at DePaul Medical Center in Norfolk, Virginia.

«Prior studies have suggested that poor baseline mental health can lead to more significant postoperative complications possibly due to impaired immune response associated with higher levels of stress,» explained Scott M. Gilbert, MD, MS, of the H. Lee Moffitt Cancer Center, Tampa, FL. «This may delay both wound healing and the ability to fight infection in the postoperative state, for example.

Led by associate professor of pathology and Yale Cancer Center member Don Nguyen, PhD, the researchers analyzed RNA from patients with disease that was limited to the lungs as well as cancers that had spread.

«This study demonstrates that targeted fusion - guided biopsy could significantly enhance our ability to identify patients with high - risk prostate cancers that need more aggressive treatment,» says lead author Mohummad Minhaj Siddiqui, MD, assistant professor of surgery at the University of Maryland School of Medicine and director of urologic robotic surgery at the University of Maryland Marlene and Stewart Greenebaum Cancer Center.

The realization that «cancer is complicated, and no single institute, country, or even continent would be able to deal with it,» led to the Stockholm Declaration, a commitment to join forces signed by the directors of 18 European cancer centers.

«One criticism of the PARP drugs is they are not active in patients who have developed resistance to other therapies, but we found veliparib appears to be effective in some platinum - resistant patients with recurrent or persistent disease,» said Robert L. Coleman, MD, lead author of the study and professor and vice chair of clinical research at the University of Texas MD Anderson Cancer Center, Houston.

«The phi test helps physicians distinguish prostate cancer from benign conditions by utilizing three different PSA markers (PSA, freePSA and p2PSA) as part of a sophisticated algorithm to more reliably determine the probability of cancer in patients with elevated PSA levels,» said Kevin Slawin, MD, director, Vanguard Urologic Institute at Memorial Hermann Medical Group, clinical professor of Urology at Baylor College of Medicine and director of Urology, Memorial Hermann Hospital ‐ Texas Medical Center, who performed some of the key research that led to the development of the phi test and who also began using the test in February.

Other main contributors include Thomas Milner, professor of biomedical engineering in UT Austin's Cockrell School of Engineering and his lab members; Jialing Zhang, research associate at the Eberlin Lab at UT Austin who led the experimental work with other lab members; Anna Sorace, assistant professor at UT Austin's Dell Medical School; Chandandeep Nagi and Wendong Yu, professors of pathology at Baylor College of Medicine, and Jinsong Liu, professor of pathology at University of Texas MD Anderson Cancer Center.

The immunotherapy drug pembrolizumab — already FDA - approved for other forms of cancer - has been found to be effective in patients with metastatic triple negative breast cancer, according to an international clinical trial led by NYU Langone's Perlmutter Cancer Ccancer - has been found to be effective in patients with metastatic triple negative breast cancer, according to an international clinical trial led by NYU Langone's Perlmutter Cancer Ccancer, according to an international clinical trial led by NYU Langone's Perlmutter Cancer CCancer Center.

A neuro - oncology research team at Dartmouth's Norris Cotton Cancer Center, led by the Director Mark A. Israel, MD with first author Gilbert J. Rahme, PhD, recently identified the transcription factor Id4 as a suppressor of tumor cell invasion in glioblastoma.

Summers and the research team, led by Dr. Mike Jensen at the Ben Towne Center for Childhood Cancer Research at Seattle Children's Research Institute, are opening PLAT - 04 after discovering that of the patients who relapsed in the PLAT - 02 trial, approximately 40 percent of them relapsed with a leukemia that evolved to circumvent the CAR T cells that were reprogrammed to detect and destroy cCancer Research at Seattle Children's Research Institute, are opening PLAT - 04 after discovering that of the patients who relapsed in the PLAT - 02 trial, approximately 40 percent of them relapsed with a leukemia that evolved to circumvent the CAR T cells that were reprogrammed to detect and destroy cancercancer.

«The compelling results seen in this global study provide unequivocal evidence supporting the clinical utility of Oncotype DX to risk - stratify patients with early stage breast cancer, and indicate that the findings are generalizable to everyday clinical practice,» said lead author Joseph A. Sparano, MD, vice-chairman of medical oncology at Montefiore Einstein Center for Cancer Care, and professor of medicine and of obstetrics, gynecology, women's health at Albert Einstein College of Medcancer, and indicate that the findings are generalizable to everyday clinical practice,» said lead author Joseph A. Sparano, MD, vice-chairman of medical oncology at Montefiore Einstein Center for Cancer Care, and professor of medicine and of obstetrics, gynecology, women's health at Albert Einstein College of MedCancer Care, and professor of medicine and of obstetrics, gynecology, women's health at Albert Einstein College of Medicine.

Jeroen Roelofs, assistant professor in the Division of Biology and a research affiliate with the university's Johnson Cancer Research Center, led a study on a specific step in the assembly of proteasomes.

No one is more pleased with the achievement — a decade in the making — than Samuel Danishefsky, a biological chemist at the Memorial Sloan - Kettering Cancer Center in New York, who led the team.

To this end Dr. Linding is currently leading high - level, strategic, multidisciplinary studies of signaling network dynamics driving cancer metastasis in collaboration with other labs at Harvard, Yale, The Jackson Laboratory, Memorial Sloan Kettering Cancer Center, MIT, andcancer metastasis in collaboration with other labs at Harvard, Yale, The Jackson Laboratory, Memorial Sloan Kettering Cancer Center, MIT, andCancer Center, MIT, and BRIC.

In a randomized, phase 2 multi-center clinical study, led by Manisha Shah, MD of The Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC — James), investigators tested the effectiveness of the targeted therapy drug, dabrafenib (pronounced «da bRAF e nib» and marketed as Tafinlar), given alone compared with the same drug given in combination with trametinib (pronounced «tra ME ti nib,» marketed at MeKinist) to treat a subset of advanced papillary thyroid cancer patients with B - raf mutaCancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC — James), investigators tested the effectiveness of the targeted therapy drug, dabrafenib (pronounced «da bRAF e nib» and marketed as Tafinlar), given alone compared with the same drug given in combination with trametinib (pronounced «tra ME ti nib,» marketed at MeKinist) to treat a subset of advanced papillary thyroid cancer patients with B - raf mutaCancer Hospital and Richard J. Solove Research Institute (OSUCCC — James), investigators tested the effectiveness of the targeted therapy drug, dabrafenib (pronounced «da bRAF e nib» and marketed as Tafinlar), given alone compared with the same drug given in combination with trametinib (pronounced «tra ME ti nib,» marketed at MeKinist) to treat a subset of advanced papillary thyroid cancer patients with B - raf mutacancer patients with B - raf mutations.

People with stage III colon cancer who regularly eat nuts are at significantly lower risk of cancer recurrence and mortality than those who don't, according to a new, large study led by researchers at Yale Cancer Ccancer who regularly eat nuts are at significantly lower risk of cancer recurrence and mortality than those who don't, according to a new, large study led by researchers at Yale Cancer Ccancer recurrence and mortality than those who don't, according to a new, large study led by researchers at Yale Cancer CCancer Center.

Data collected during a long - term health study provides additional evidence for a link between increased risk of cancer in individuals with advanced gum disease, according to a new collaborative study led by epidemiologists Dominique Michaud at Tufts University School of Medicine and Elizabeth Platz of the Johns Hopkins Bloomberg School of Public Health and Kimmel Cancer Ccancer in individuals with advanced gum disease, according to a new collaborative study led by epidemiologists Dominique Michaud at Tufts University School of Medicine and Elizabeth Platz of the Johns Hopkins Bloomberg School of Public Health and Kimmel Cancer CCancer Center.

«It's incredibly encouraging to find possible new options for patients with an aggressive cancer like triple negative breast cancer, and that studies conducted by separate teams at leading institutions agree on the implications of the findings,» said Alan Ashworth, PhD, FRS, president of UCSF Helen Diller Family Comprehensive Cancer Center, and former CEO of thcancer like triple negative breast cancer, and that studies conducted by separate teams at leading institutions agree on the implications of the findings,» said Alan Ashworth, PhD, FRS, president of UCSF Helen Diller Family Comprehensive Cancer Center, and former CEO of thcancer, and that studies conducted by separate teams at leading institutions agree on the implications of the findings,» said Alan Ashworth, PhD, FRS, president of UCSF Helen Diller Family Comprehensive Cancer Center, and former CEO of thCancer Center, and former CEO of the ICR.

«Over the past several years, with advances in technology, radiation to only the surgical bed of the resected lesion has become of interest,» said Anita Mahajan, MD, professor of radiation oncology at MD Anderson Cancer Center in Houston and lead author of the study.

By combining two modalities of imaging, investigators from Norris Cotton Cancer Center at Dartmouth, led by Keith Paulsen, PhD with first author Michael Mastanduno and collaborators from Xijing Hospital in Xian, China, demonstrated that a dual breast exam using MRI and Near Infrared Spectral Tomography (NIRST) is feasible and more accurate than MRI alone.

«Our case studies showed similar survival with the use of stereotactic radiation therapy compared with surgery,» said lead author Dr. Raquibul Hannan, Assistant Professor of Radiation Oncology and co-leader of the Kidney Cancer Program at the Harold C. Simmons Comprehensive Cancer Center.

The researchers, led by Professor Bernd Pichler at the Werner Siemens Imaging Center, worked with dermatologists, pathologists and immunologists at the University hospitals and at the German Consortium for Translational Cancer Research.

The research team is led by Carl June, MD, the Richard W. Vague Professor in Immunotherapy in the department of Pathology and Laboratory Medicine and director of Translational Research in the Abramson Cancer Center, along with David Porter, MD, the Jodi Fisher Horowitz Professor in Leukemia Care Excellence and director of Blood and Marrow Transplantation in the Abramson Cancer Center.

«These findings clearly point to the very important role that health care providers can play in increasing coverage with this safe and effective vaccine,» said lead author Linda M. Niccolai, Ph.D., associate professor in the school's Department of Epidemiology of Microbial Diseases and member of the Cancer Prevention and Control Program of the Yale Cancer Center.

One report, focusing on clinical trial patients with advanced kidney cancer treated with checkpoint inhibitors, is from scientists at Dana - Farber Cancer Institute and the Broad Institute of MIT and Harvard, led by Eliezer Van Allen, MD, of Dana - Farber and the Broad, and Toni Choueiri, MD, director of the Lank Center for Genitourinary Oncology at Dana - Fcancer treated with checkpoint inhibitors, is from scientists at Dana - Farber Cancer Institute and the Broad Institute of MIT and Harvard, led by Eliezer Van Allen, MD, of Dana - Farber and the Broad, and Toni Choueiri, MD, director of the Lank Center for Genitourinary Oncology at Dana - FCancer Institute and the Broad Institute of MIT and Harvard, led by Eliezer Van Allen, MD, of Dana - Farber and the Broad, and Toni Choueiri, MD, director of the Lank Center for Genitourinary Oncology at Dana - Farber.

«In addition to having a higher prevalence of triple - negative breast cancers than Caucasian women — something that has been documented in previous studies — we found that African American women with breast cancer had a significantly higher prevalence of the TP53 driver mutation, basal tumor subtype and greater genomic diversity within tumors, all of which suggest more aggressive tumor biology,» says Tanya Keenan, MD, of the MGH Cancer Center, lead author of the cancer had a significantly higher prevalence of the TP53 driver mutation, basal tumor subtype and greater genomic diversity within tumors, all of which suggest more aggressive tumor biology,» says Tanya Keenan, MD, of the MGH Cancer Center, lead author of the Cancer Center, lead author of the study.

«With head and neck cancer, we often clear patients of cancer only to see it come back with deadly consequences a few years later,» said lead author Julie Bauman, M.D., M.P.H., co-director of the UPMC Head and Neck Cancer Center of ExcelleWith head and neck cancer, we often clear patients of cancer only to see it come back with deadly consequences a few years later,» said lead author Julie Bauman, M.D., M.P.H., co-director of the UPMC Head and Neck Cancer Center of Excelcancer, we often clear patients of cancer only to see it come back with deadly consequences a few years later,» said lead author Julie Bauman, M.D., M.P.H., co-director of the UPMC Head and Neck Cancer Center of Excelcancer only to see it come back with deadly consequences a few years later,» said lead author Julie Bauman, M.D., M.P.H., co-director of the UPMC Head and Neck Cancer Center of Excellewith deadly consequences a few years later,» said lead author Julie Bauman, M.D., M.P.H., co-director of the UPMC Head and Neck Cancer Center of ExcelCancer Center of Excellence.

The study was led by UCLA's Jonsson Comprehensive Cancer Center member Dr. Joanne Weidhaas in collaboration with colleagues at the NRG Oncology RTOG.

«There has been a great deal of debate about the effectiveness of bevacizumab in treating patients with glioblastoma,» says lead author Derek Johnson, M.D., a neuro - oncologist at Mayo Clinic Cancer Center.

A group led by Eleanor Rogan, a cancer researcher at the University of Nebraska Medical Center in Lincoln, took samples of healthy breast tissue from women with and without cancer and measured the amounts of estrogen derivatives.

A multi-institutional international study led by scientists at The University of Texas MD Anderson Cancer Center has revealed new information about how molecules called long non-coding RNAs (lncRNA) interact with HIF - 1, a signaling pathway that is overexpressed in many cancers.

A multi-center study led by Fred Hutchinson Cancer Research Center has found that high - dose supplementation with both the trace element selenium and vitamin E increase the risk of high - grade prostate cCancer Research Center has found that high - dose supplementation with both the trace element selenium and vitamin E increase the risk of high - grade prostate cancercancer.

«We already know that coordinated, patient - centered palliative care improves care quality, enhances survival, and reduces costs for persons with cancer,» said R. Sean Morrison, MD, Director of the National Palliative Care Research Center and Professor of Geriatrics and Palliative Medicine, Icahn School of Medicine at Mount Sinai and lead author of the study.

«We urgently need markers to predict which therapies are going to be effective and which will not be effective in individual patients with advanced prostate cancer,» said lead study author Emmanuel Antonarakis, MD, an assistant professor of oncology and urology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore, Md. «AR - V7 testing may be extremely valuable in guiding treatment decisions for men with hormone - resistant disease in the near future.&cancer,» said lead study author Emmanuel Antonarakis, MD, an assistant professor of oncology and urology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore, Md. «AR - V7 testing may be extremely valuable in guiding treatment decisions for men with hormone - resistant disease in the near future.&Cancer Center at Johns Hopkins in Baltimore, Md. «AR - V7 testing may be extremely valuable in guiding treatment decisions for men with hormone - resistant disease in the near future.»

«We wanted to see whether very - large - scale screening across a diverse collection of cancer cell lines and a large number of drugs could yield new combinations for patients with cancer,» says Adam Friedman, MD, PhD, of the CBRC and the MGH Cancer Center, who led the cancer cell lines and a large number of drugs could yield new combinations for patients with cancer,» says Adam Friedman, MD, PhD, of the CBRC and the MGH Cancer Center, who led the cancer,» says Adam Friedman, MD, PhD, of the CBRC and the MGH Cancer Center, who led the Cancer Center, who led the study.

«Historically, when treating early lung cancer with radiotherapy, progression at the site of the primary tumor was the most common failure resulting in suffering and death,» said lead study author Robert Timmerman, MD, professor and vice chair of the department of radiation oncology at the University of Texas Southwestern Medical Center in Dallas.

«More and more patients are being cured of lung cancer, with both surgery and radiation as good treatment options,» said lead author Nirav S. Kapadia, MD, of Dartmouth - Hitchcock Medical Center in New Hampshire.

The study, led by Deborah Armstrong at the Johns Hopkins Kimmel Cancer Center in Baltimore, Maryland, builds upon evidence from eight other clinical trials showing an overall survival benefit of approximately one year for women treated with IP chemotherapy after «optimal debulking» — surgery to remove most, if not all, of the cancer in the abCancer Center in Baltimore, Maryland, builds upon evidence from eight other clinical trials showing an overall survival benefit of approximately one year for women treated with IP chemotherapy after «optimal debulking» — surgery to remove most, if not all, of the cancer in the abcancer in the abdomen.

A team led by epidemiologist Larry Clark of the Arizona Cancer Center in Tucson had observed lower rates of skin cancer among people with high levels of selCancer Center in Tucson had observed lower rates of skin cancer among people with high levels of selcancer among people with high levels of selenium.

Taking the focus off pain management and specific post-treatment symptoms, and putting it on quality of life defined as «active engagement,» a team from Dartmouth's Norris Cotton Cancer Center, led by Mark T. Hegel, PhD with first - author Kathleen D. Lyons, ScD, established and tested a new paradigm for working with breast cancer survCancer Center, led by Mark T. Hegel, PhD with first - author Kathleen D. Lyons, ScD, established and tested a new paradigm for working with breast cancer survcancer survivors.

Stahlberg currently leads high - performance computing at the Frederick National Laboratory, working with the National Cancer Institute Center for Biomedical Informatics and Information Technology.

This helps to relieve some of the stress new patients and their families may experience leading up to that first appointment with a Cancer Center doctor.

Based on our findings, the occurrence of cancer is much higher in adults over 75 years of age compared with the proportion of patients in this age group who enroll in clinical trials,» said lead study author Bindu Kanapuru, MD, medical officer in the Division of Hematology Products, Office of Hematology and Oncology Products in the US Food and Drug Administration's (FDA) Center for Drug Evaluation and Research, who presented the results at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition, held December 9 — 12 in Atlanta.

In a recent multi-institutional phase II trial of Onyx - 015 led by investigators at University of Texas M.D. Anderson Cancer Center, 30 patients with advanced head and neck cancer, most of whom had failed surgery or radiation therapy, were trCancer Center, 30 patients with advanced head and neck cancer, most of whom had failed surgery or radiation therapy, were trcancer, most of whom had failed surgery or radiation therapy, were treated.

«The primary goal of GEP testing is to identify patients at high recurrence risk who will benefit from chemotherapy, while allowing patients with a low recurrence risk to forego chemotherapy, potentially offsetting the test costs with savings from reductions in chemotherapy use,» wrote authors led by Young Chandler, PhD, of the Georgetown Lombardi Comprehensive Cancer Center in Washington, DC.

Quizartinib inhibits FLT3 kinase activity and induced about a 50 % composite response rate among patients with FLT3 - ITD mutations in phase I and II studies, said lead author Mahesh Swaminathan, MD of the University of Texas MD Anderson Cancer Center in Houston.